BAT2022

Bio-Thera Solutions · Phase 1 active Small molecule

At a glance

Generic name	BAT2022
Also known as	BAT2022 for Injection (bispecific neutralizing antibody targeting the receptor binding domain (RBD) of spike of SARS-CoV-2)
Sponsor	Bio-Thera Solutions
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluate the Pharmacokinetics of BAT2022 in Healthy Chinese Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BAT2022 CI brief — competitive landscape report
BAT2022 updates RSS · CI watch RSS
Bio-Thera Solutions portfolio CI